Guardant Health Inc (NASDAQ: GH) has experienced a rise in its stock price by 14.87 compared to its previous closing price of 17.96. However, the company has seen a gain of 17.48% in its stock price over the last five trading days. Seeking Alpha reported 2024-03-22 that GH can prove to the market they have a competitive product in Shield that can gain a foothold in the roughly 50m unscreened CRC patient population. Shield’s strongest adherence rate, with the potential for on-par sensitivity submission within 18 months will drive adoption. Currently trading over 1.5 STD below historical discount to Exact Sciences (EXAS), their main comp.
Is It Worth Investing in Guardant Health Inc (NASDAQ: GH) Right Now?
Moreover, the 36-month beta value for GH is 0.85. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GH is 115.90M and currently, short sellers hold a 6.69% of that float. On April 01, 2024, GH’s average trading volume was 1.68M shares.
GH’s Market Performance
GH stock saw an increase of 17.48% in the past week, with a monthly gain of 10.14% and a quarterly increase of -26.37%. The volatility ratio for the week is 6.06%, and the volatility levels for the last 30 days are 5.23% for Guardant Health Inc (GH). The simple moving average for the past 20 days is 12.31% for GH’s stock, with a -27.21% simple moving average for the past 200 days.
Analysts’ Opinion of GH
Raymond James gave a rating of “Outperform” to GH, setting the target price at $27 in the report published on November 13th of the previous year.
GH Trading at -0.07% from the 50-Day Moving Average
After a stumble in the market that brought GH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.76% of loss for the given period.
Volatility was left at 5.23%, however, over the last 30 days, the volatility rate increased by 6.06%, as shares surge +8.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.58% lower at present.
During the last 5 trading sessions, GH rose by +17.48%, which changed the moving average for the period of 200-days by -40.60% in comparison to the 20-day moving average, which settled at $18.45. In addition, Guardant Health Inc saw -23.73% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GH starting from Kalia Kumud, who purchase 2,187 shares at the price of $17.82 back on Mar 18 ’24. After this action, Kalia Kumud now owns 12,722 shares of Guardant Health Inc, valued at $38,963 using the latest closing price.
Joyce Meghan V., the Director of Guardant Health Inc, sale 100 shares at $19.05 during a trade that took place back on Mar 04 ’24, which means that Joyce Meghan V. is holding 4,521 shares at $1,905 based on the most recent closing price.
Stock Fundamentals for GH
Current profitability levels for the company are sitting at:
- -1.0 for the present operating margin
- 0.85 for the gross margin
The net margin for Guardant Health Inc stands at -0.85. The total capital return value is set at -0.36. Equity return is now at value -438.13, with -28.23 for asset returns.
Based on Guardant Health Inc (GH), the company’s capital structure generated 0.88 points at debt to capital in total, while cash flow to debt ratio is standing at -0.28. The debt to equity ratio resting at 7.36. The interest coverage ratio of the stock is 219.06.
Currently, EBITDA for the company is -519.63 million with net debt to EBITDA at -0.41. When we switch over and look at the enterprise to sales, we see a ratio of 4.84. The receivables turnover for the company is 6.35for trailing twelve months and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.54.
Conclusion
To wrap up, the performance of Guardant Health Inc (GH) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
